FeesSafety
Pluang+

Theriva Biologics announces 1-for-30 reverse stock split effective Dec 2, 2026 to meet NYSE price requirements

Company Fundamentals
22 Nov 2026, 01:45 WIB
Na
View Source
Neutral
Theriva Biologics announces 1-for-30 reverse stock split effective Dec 2, 2026 to meet NYSE price requirements

Theriva Biologics, a clinical-stage biotech company, announced a 1-for-30 reverse stock split effective December 2, 2026. This move reduces the number of outstanding shares from about 45.9 million to approximately 1.53 million to meet the New York Stock Exchange's minimum price requirements. Shareholders will automatically receive adjusted shares without needing to take action, and the company's stock will continue trading under the symbol TOVX with a new CUSIP number. The split aims to maintain compliance with NYSE listing standards and support the company's ongoing development of cancer therapies.

Theriva Biologics' announcement of a 1-for-30 reverse stock split provides context for market conditions. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 21, 2026 22:12 WIB: out of 150 priced US health-sector stocks, 31 rose and 117 fell. Notable movers include SANA at USD 1.59 with a 1-day change of -8.62% and Pluang order activity showing 66% Sell / 34% Buy, ALMS at USD 3.96 down 8.55%, and IBRX at USD 6.02 down 8.37%.

More News

Nebius shares drop 40% despite strong growth; $7B ARR target delayed to Feb 2027, long-term outlook remains positive.

Nebius shares drop 40% despite strong growth; $7B ARR target delayed to Feb 2027, long-term outlook remains positive.

Nebius' stock fell over 40% in a month due to a two-month delay in reaching its $7 billion annual recurring revenue (ARR) target, now expected by February 2027. This delay was caused by third-party provider issues, but the company is improving its da...

Market News
Bullish
41 minutes ago
FitLife Brands cuts costs and locks in raw material prices to protect margins amid stable revenue.

FitLife Brands cuts costs and locks in raw material prices to protect margins amid stable revenue.

FitLife Brands reported a 9% revenue increase to $25.6 million in Q3 2026 while managing cost pressures through strategic forward purchases of whey protein and fish oil, expanding working capital by $3.5 million to hedge against commodity inflation. ...

Company Fundamentals
Bullish
46 minutes ago
Weibo's Q3 revenue falls 7% amid cautious ad spending; AI tools boost ad campaign setup efficiency.

Weibo's Q3 revenue falls 7% amid cautious ad spending; AI tools boost ad campaign setup efficiency.

Weibo reported a 7% year-over-year decline in total third-quarter 2026 revenues to $410.2 million, with advertising revenue down 8% to $344.1 million due to reduced ad budgets in key consumer sectors. Despite this, targeted content marketing, especia...

Company Fundamentals
Neutral
50 minutes ago
Nvidia seen as top AI stock to buy during market downturn due to strong fundamentals and growth potential.

Nvidia seen as top AI stock to buy during market downturn due to strong fundamentals and growth potential.

Nvidia is highlighted as a strong AI stock choice during a market crash because of its robust financial health, critical role in AI technology, and significant growth potential. Despite recent challenges like CEO changes and regulatory concerns, Nvid...

Market News
Bullish
51 minutes ago
Vanguard Energy ETF gains 43% as rising rates boost energy stocks ahead of Fed hikes.

Vanguard Energy ETF gains 43% as rising rates boost energy stocks ahead of Fed hikes.

The Vanguard Energy ETF has surged 43% this year, benefiting from rising oil prices and interest rates. With the Federal Reserve expected to raise rates again in December and possibly March 2027, energy stocks like those in this ETF serve as effectiv...

Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App